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Abstract
Background: Gene expression assays have been shown to yield high quality genome-wide data from partially
degraded RNA samples. However, these methods have not yet been applied to postmortem human brain tissue,
despite their potential to overcome poor RNA quality and other technical limitations inherent in many assays. We
compared cDNA-mediated annealing, selection, and ligation (DASL)- and in vitro transcription (IVT)-based genome-
wide expression profiling assays on RNA samples from artificially degraded reference pools, frozen brain tissue, and
formalin-fixed brain tissue.
Results: The DASL-based platform produced expression results of greater reliability than the IVT-based platform in
artificially degraded reference brain RNA and RNA from frozen tissue-based samples. Although data associated with
a small sample of formalin-fixed RNA samples were poor when obtained from both assays, the DASL-based
platform exhibited greater reliability in a subset of probes and samples.
Conclusions: Our results suggest that the DASL-based gene expression-profiling platform may confer some
advantages on mRNA assays of the brain over traditional IVT-based methods. We ultimately consider the
implications of these results on investigations of neuropsychiatric disorders.
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Background
Gene expression profiling investigations involving post-
mortem brain tissue of cases with neuropsychiatric dis-
orders such as autism have been limited due to tissue
availability and tissue quality [1-3]. Such investigations,
however, are critical for understanding uniquely human
disorders [4]. While experimenters cannot control tissue
availability, novel technologies can be employed to uti-
lize the precious and scarce tissue resources available
from brain banks even if preservation quality is not
ideal [5-7].
The cDNA-mediated annealing, selection, and ligation
(DASL) gene expression assay has been shown to pro-
duce highly reliable results when applied to formalin-
fixed, paraffin-embedded tissues [7,8]. To overcome the
difficulties associated with poly A/oligo-dT-based prim-
ing in special experimental conditions such as with pro-
filing partially degraded RNA, the DASL-based assay
uses random priming at the cDNA synthesis step. It
generates first strand cDNA to minimize variation dur-
ing random priming and avoids biases associated with
sample amplification and labeling from multiple rounds
of random priming [9]. Furthermore, the assay requires
only a ~50 nucleotide target sequence for query oligo-
nucleotide annealing, which makes it effective for quan-
tifying partially degraded RNA samples.
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applied in the study of human liver, esophagus, breast,
prostate, ovarian, and other biopsy and autopsy tissues
[8,10-13]. It can be extended for use in a genome-wide
format, which may be of value in the elucidation of
genes mediating neuropsychiatric diseases [4]. However,
it has not yet been applied to postmortem frozen and
formalin-fixed brain tissue, despite its potential benefits
when assaying samples with low RNA quality.
In this study, we investigated the utility of the stan-
dard IVT- and DASL- based genome-wide expression
profiling assays in the context of a clinically important
neuropsychiatric disorder, autism. Our objectives were
to: 1) compare the quality of microarray data from IVT-
based and DASL-based platforms on artificially degraded
reference RNA; and 2) compare the quality of microar-
ray data from these two RNA profiling platforms on
postmortem frozen and formalin-fixed brain tissue.
Results
DASL-based expression profiling is more reliable than
IVT-based profiling on artificially degraded brain
reference RNA
To first assess the reliability of IVT- and DASL-based
platforms in expression profiling of artificially degraded
reference RNA samples, we performed these two assays
on brain and pooled reference RNA heated at 95°C for
0 (intact RNA), 10, 30, and 60 minutes (Additional File
1). Heating fragments the reference RNA, which simu-
lates RNA degradation conditions in vivo.T h em o r e
time that RNA is subjected to heating, the more frag-
mented the RNA becomes (Additional File 1).
Fold change differences between brain reference RNA
and pooled reference RNA were used to assess the relia-
bility of gene expression profiles at different levels of
RNA fragmentation (Figure 1). The IVT-based assay
yielded low correlations between expression profiles
detected in intact RNA, which was used as the standard,
and degraded RNA. Correlation with intact RNA yielded
a correlation coefficient R
2 = 0.717 at 10 minutes of
heating, R
2 = 0.154 at 30 minutes, and R
2 =0 . 0 3 9a t6 0
minutes. In contrast, even extremely degraded RNA pro-
filed by the DASL-based assay yielded higher correla-
tions with intact RNA. Correlation with intact RNA
yielded a correlation coefficient R
2 = 0.826 at 10 min-
utes of heating, R
2 = 0.558 at 30 minutes, and R
2 =
0.272 at 60 minutes.
High direct correlations were also achieved using the
DASL-based assay between detected genes of intact
reference brain RNA and degraded reference brain RNA
samples only (Figures 2 and Additional File 2). Correla-
tion with intact RNA yielded a correlation of 0.98 at 10
minutes, 0.92 at 30 minutes, and 0.82 at 60 minutes of
degradation. Similarity between degraded and intact
samples achieved by the IVT-based assay, however, was
much lower. Correlations of 0.93 at 10 minutes, 0.75 at
30 minutes, and 0.5 at 60 minutes with intact RNA
were found. In general, partial RNA degradation affected
both assays (Additional File 3), but the IVT-based assay
was affected more severely than the DASL-based assay
(Figures 1 and 2, and Additional File 4) as evidenced by
lower correlations of degraded reference samples with
standard intact conditions.
DASL-based platform is more reliable than IVT-based
platform on RNA from postmortem frozen brain tissue
but not formalin-fixed tissue
We next assessed the performance of DASL- and IVT-
based assays on RNA extracted from postmortem frozen
and formalin-fixed brain tissue (Table 1). Generally,
average probes detected, average probe concordance,
and average signal were higher for the DASL-based
assay than the IVT-based assay for RNA extracted from
frozen tissue and formalin fixed tissue (Figure 3). Aver-
age self-reproducibility was also higher for the DASL-
based assay than for the IVT-based assay in frozen tis-
sue, but not formalin fixed tissue. Upon examination of
scatterplots of the formalin fixed genome-wide data,
however, it was apparent that the high correlation
between technical replicates in the IVT-based assay was
due to detected expression only at background levels for
these samples (Additional File 5).
Through examining a small number of samples
assayed on both IVT-based and DASL-based platforms,
we observed that the IVT-based assay was more severely
affected by RNA degradation than the DASL-based
assay with RNA extracted from brain tissues also, in
accordance with the reference RNA experiments (Figure
2). For example, though correlations between detected
probes decreased with decreasing RIN in both assays,
correlation between a sample with RIN 6.3 and a sample
with RIN 2.4 was 0.84 in DASL-based assay, but only
0.14 in IVT-based assay. With few exceptions, correla-
tions between the same degraded samples and relatively
intact RNA samples from frozen tissue and reference
RNA were higher between those assayed by the DASL-
based assay than by IVT-based assay. In addition, distri-
butions of detected probes were clearly affected for
IVT-based profiling of samples with low RIN, but this
was not the case in DASL-based profiling (Additional
File 6). In general, correlations of detected probes from
the same samples between platforms were low (Addi-
tional File 7). Correlations of samples from the same
case (UMB1796), frozen and formalin fixed, within and
between platforms were also low (Additional File 8).
Nonetheless, neither platform appeared to produce
reliable results using RNA from formalin-fixed brain tis-
sue (Additional Files 5 and 8). Few genes across samples
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Page 2 of 12Figure 1 Fold change differences between degraded brain and pooled reference RNA samples show greater similarity to intact RNA
in profiling by DASL- (right column) than by IVT-based (left column) approach. Scatterplots depicting unnormalized log2 fold change
[Log2(Brain/Pooled)] of detected intensity values between intact brain and pooled reference RNA samples, and correlations (R
2) with artificially
degraded brain and pooled reference RNA samples at 10 min (A), 30 min (B) and 60 min (C) are shown. For example, the log fold change
difference between brain and pooled RNA heated for 60 minutes was correlated with the intact RNA R
2 = 0.039 using the IVT-based approach,
but R
2 = 0.272 using the DASL-based approach. B, brain reference RNA; P, pooled reference RNA; 0, intact; 10, heated at 95°C for 10 min; 30,
heated at 95°C for 30 min; 60, heated at 95°C for 60 min.
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Page 3 of 12were detected above baseline on either platform, but a
subset of probes detected above baseline levels in these
samples on the DASL-based assay may show some
reproducibility (Additional File 5).
Predictors of variance in tissue dataset
We next analyzed variance prediction to understand
important experimental and subject factors of gene
expression differences in our dataset. These analyses can
help determine statistical preprocessing that must be
performed to prepare the dataset for differential expres-
sion analysis, and can indicate experimental considera-
tions for future experiments. Hierarchical clustering by
average linkage showed grouping of samples by assay
type (DASL/IVT) and tissue preservation (frozen/forma-
lin fixed; Figure 4A).
To quantify these and other predictors of variance in
the dataset, we performed Multivariate Distance Matrix
Regression (MDMR) analysis [14]. Multiple regression
MDMR (Figure 4B) showed that tissue preservation
Figure 2 Assay performance on RNA from frozen tissues and artificially degraded reference RNA. DASL-based expression profiling
produces higher correlations between frozen tissue-based RNA samples and reference RNA samples regardless of RNA degradation. Scatterplots,
histograms, and correlation of frozen tissue-based RNA and reference RNA profiling on IVT- and DASL-based platforms are shown. For example,
correlation between UMB4849 (RIN = 6.3) and UMB4721 (RIN = 2.4) is 0.14 for IVT (four top left boxes) but 0.84 for DASL (four top left boxes
under “DASL Frozen”). For the IVT-based samples, histogram shows clustering of detected intensities for UMB4721 at background levels, and
skewing of the scatterplot away from y = x. In contrast, the distribution of UMB4721 profiled by DASL appeared similar to UMB4849, and the
scatterplot showed adherence to the y = x line. RIN of tissue sample or reference sample are listed in the histogram box. Cor = correlation.
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Page 4 of 12Table 1 Frozen and formalin fixed tissue samples assayed
Case ID Diagnosis Age Sex COD PMI RIN Frozen/Fixed
B6399 Autism 2 M Drowning 4 6 Frozen
UMB4671 Autism 4 F Accident, multiple injuries 13 7.7 Frozen
B1469 Autism 5 M Unknown 42.8 2.3 Frozen
B5569 Autism 5 M Asphyxia due To Drowning 25.5 2.5 Frozen
UMB1349 Autism 5 M Drowning 39 - Frozen
UMB1174 Autism 7 F Seizure, Hypotension 14 - Frozen
UMB4849 Autism 7 M Drowning 20 6.3 Frozen
B5666 Autism 8 M Sarcoma 22.2 5 Frozen
UMB4231 Autism 8 M Drowning 12 - Frozen
UMB4721 Autism 8 M Drowning 16 2.4 Frozen
UMB1182 Autism 9 F Smoke Inhalation 24 - Frozen
B4925 Autism 9 M Seizure Disorder 27 2.2 Frozen
UMB797 Autism 9 M Drowning 13 - Frozen
UMB4899 Autism 14 M Drowning 9 - Frozen
B7079 Autism 15 M Asphyxia 23 5.7 Frozen
B5223
(M1106)
Autism 16 M Stopped Breathing 47.9 - Fixed
B6184 Autism 18 F Seizures 7 3.6 Frozen
B5144 Autism 20 M Auto Trauma 23.7 - Frozen
B6337 Autism 22 M Aspirated on vomit/Seizure 25 - Frozen
B5000 Autism 27 M Drowning 8.3 - Frozen
B6994 Autism 28 M Seizures 43.25 3 Frozen
B6640 Autism 29 F Seizures 17.83 - Frozen
B5173 Autism 30 M GastroIntestinal Bleeding, seizures 20.3 - Frozen
B6677 Autism 30 M Congestive heart failure 16 - Frozen
B6401 Autism 39 M Cardiac Tamponade 14 2.3 Frozen
UMB1445 Autism 45 M Complications of ALS/Autism 23 - Frozen
B7085 Autism 49 F Colorectal cancer spread through abdomen 21 3.4 Frozen
B7109 Autism 51 M Myocardial infarction 22 4 Frozen
B4498 Autism 56 M Anoxic Encephalopathy 20 - Frozen
B6736 Control 4 F Acute bronchipneumonia after tonsillectomy 17 6.3 Frozen
UMB1499 Control 4 F Lymphocytic Myocarditis 21 6.5 Frozen
UMB1185 Control 4 M Drowning 17 2.1 Frozen
UMB4670 Control 4 M Commotio Cordis 17 2.2 Frozen
UMB1377 Control 6 F Drowning 20 - Frozen
UMB1500 Control 6 M Multiple Injuries 19 1.8 Frozen
UMB4898 Control 7 M Drowning 12 5.1 Frozen
UMB1674 Control 8 M Drowning 36 - Frozen
UMB1860 Control 8 M Cardiac arrythmia 5 - Frozen
UMB1407 Control 9 F Seizure, Asthma 20 5.7 Frozen
UMB1650 Control 10 M Sudden Unexpected Death 24 2.1 Frozen
UMB1714 Control 12 M Cardiac arrythmia 22 2.5 Frozen
UMB4787 Control 12 M Asthma 15 6.4 Frozen
UMB1670
(M806)
Control 13 M Asphyxia By Hanging 5 - Fixed
UMB4722 Control 14 M MVA Multiple Injuries 16 1.8 Frozen
UMB4638 Control 15 F Chest Injuries 5 - Frozen
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Page 5 of 12method (frozen or fixed) accounted for 27% of the var-
iance in the dataset, followed, in significance, by assay
type [IVT or DASL; cumulative percentage of variance
explained (PVE) = 10%], batch (PVE = 26%), age of the
case (PVE = 0.9%), diagnosis (PVE = 0.8%), gender (PVE
= 0.5%), and postmortem interval (PVE = 0.3%).
In a small sample of cases with available RIN (N = 4)
and assayed on both IVT- and DASL-based assays, RIN
also explained a large percentage of variability in the
expression data. However, the influence of RIN on the
IVT-processed samples (PVE = 82.45%, p = 0.21) in sin-
gle regression MDMR was greater than that on the
DASL-processed samples (PVE = 64.52, p = 0.1178).
These results confirm that the IVT-based assay is more
greatly influenced by differences in RNA degradation
than the DASL-based assay.
Validation of microarray results by qPCR
QPCR validation of the DASL-based microarray data
was performed on a subset of genes. We compared the
log2 fold changes of the qPCR data with the log2 trans-
formed, quantile normalized data. Using a Spearman’s
rank correlation, the log2 fold changes of these 19 genes
(Table 2) across qPCR and DASL-based microarray plat-
forms were found to be correlated at R = 0.78 (p =
0.000075, DF = 17; Additional File 9).
Discussion
Recent advances in gene expression technology have
made genome-wide expression profiling possible in
partially degraded RNA samples [5,7]. DASL
technology has been applied reliably to even formalin
fixed, paraffin-embedded tissues from a range of tissue
sources [8,10-13]. It has, however, not yet been uti-
lized to profile expression in brain tissue, in which
RNA degradation levels are known to be high and
availability is limited [1-3]. We have shown that the
DASL-based genome-wide expression-profiling
approaches applied to partially degraded brain-specific
reference RNA and postmortem brain tissue-extracted
RNA may confer some advantages over traditional
IVT-based methods. Our observations raise questions
about the reliability of the assays that could impact
interpretation of association analyses involving gene
expression levels.
The greater the degradation of RNA, the less reliable
results from IVT- and DASL-based platforms become.
Therefore, although the DASL-based approach appeared
to recover more reliable gene expression values from
partially degraded RNA samples, reliable results may
still not be gleaned from the most severely degraded
and chemically modified RNA samples such as from for-
malin-fixed brain tissue. The main cause of failure using
DASL in formalin-fixed brain tissue may be difficulty
with performing the reverse transcription step. Unfortu-
nately, even though the DASL-based assay performed
better than the IVT-based assay in limited brain frozen
tissues, our sample sizes were too small to make conclu-
sive arguments about the relative efficacy of DASL- and
IVT-based platforms on RNA extracted from frozen and
formalin fixed tissues. Our results, however, suggest that
the DASL-based platform may confer some advantages
Table 1 Frozen and formalin fixed tissue samples assayed (Continued)
B6207 Control 16 M Heart attack/disease 26.2 - Frozen
B6756 Control 16 M Myocardial infarction 22 - Frozen
UMB1796
(EC6)
Control 16 M Multiple Injuries 16 - Frozen and Fixed
B5251 Control 19 M Pneumonia/respiratory infection 19 3.5 Frozen
UMB1649 Control 20 M Multiple Injuries 22 4.9 Frozen
BTB3960 Control 25 F Gunshot to the Chest 26 - Frozen
UMB818 Control 27 M Multiple Injuries 10 1.9 Frozen
B5873 Control 28 M Unknown 23.3 - Frozen
B5334 Control 30 M Asphyxia 14.83 5.7 Frozen
B5352 Control 31 M Asphyxia 33 3.8 Frozen
B5813 Control 41 M Unknown 27 5.2 Frozen
BTB-3859
(EC5)
Control 44 M Unknown 30 - Fixed
B6208 Control 50 F Heart attack/disease 20 - Frozen
B4756 Control 56 M Myocardial infarction 23 5.9 Frozen
B6860 Control 56 M Unknown 22 6.3 Frozen
Case ID, diagnosis, age, gender, cause of death (COD), postmortem interval (PMI), RNA Integrity Number (RIN), and preservation method of the postmortem
human brain samples assayed in this study are listed.
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Page 6 of 12for profiling partially degraded RNA from frozen brain
tissue.
Through the examination of the expression datasets in
tissue-based RNA samples from control and autistic
cases, we explored important factors to consider in post-
mortem brain tissue expression profiling. The most
important explanatory variable of gene expression pro-
file variance across samplesi no u rd a t a s e tw a si nf a c t
not the platform on which the RNA was assayed, but
how the tissue was preserved. This result has important
implications for brain banks in the methods used for
preserving RNA [15] and for interpreting and comparing
across brain gene expression studies, especially in neu-
ropsychiatric disorders [1] with a spectrum of pheno-
types like autism. Though in general the DASL-based
approach is more reliable than the IVT-based approach
for profiling degraded mRNA samples, our MDMR ana-
lyses suggest that RNA degradation and other factors
still play important roles in determining dataset var-
iance, thereby potentially confounding differential
expression analyses. These additional factors may be
dealt with during data preprocessing steps using such
statistical tools as ComBat [16], and is described in
Chow and Pramparo et al.: Early brain gene expression
and copy number anomalies in autism, submitted.
Conclusions
Nonetheless, the study of neuropsychiatric disorders
may benefit from DASL-based expression profiling tech-
nology, especially when investigating molecular path-
ways involved in diseases that cannot be modeled by
animals [4]. This platform and other expression profiling
methods will be vital in helping make use of scarce and
precious brain tissue to elucidate uniquely human
genetic pathogenic mechanisms.
Methods
Artificial Degradation of Reference RNA
Ambion
® human reference brain RNA and Stratagene
®
reference pooled RNA samples were heated at 95°C for
0, 10, 30, and 60 minutes to artificially degrade them.
Samples were analyzed using BioAnalyzer
® (Agilent
Technologies) to visualize levels of degradation (Addi-
tional File 1). Combinations of 75% brain reference
RNA and 25% pooled reference RNA, and 75% pooled
reference RNA and 25% brain reference RNA were also
Figure 3 Probe detection of two assays with RNA from frozen and fixed tissues. (A) Summary of detected probes, probe concordance
(detection p-value < 0.05 between technical replicates) and reliability of frozen and fixed tissue-based RNA profiling (correlation between
technical replicates) on IVT- and DASL-based platforms are shown. DASL appears to confer some advantage over traditional IVT-based methods
for tissue-based expression profiling. (B) Detected genes at p < 0.01 and p < 0.05 of frozen and fixed tissue-based RNA profiling on IVT- and
DASL-based platforms. (C) Average signal detected from frozen and fixed tissue-based RNA profiling on IVT- and DASL-based platforms.
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then prepared for profiling on microarray platforms as
described below.
Frozen and formalin-fixed postmortem human brain
samples for gene expression profiling
57 frozen blocks of fresh frozen brain tissue and 4
blocks of formalin-fixed brain tissue from the prefrontal
cortex of controls and autistic, male and female cases
were obtained from the Harvard Brain and Tissue
Resource Center (United States Public Health Service)
a n df r o mt h eU n i v e r s i t yo fM i a m i / U n i v e r s i t yo fM a r y -
land Brain and Tissue Bank (National Institute of Child
Health and Human Development; Table 1).
Diagnostic criteria of Autistic Disorder was verified for
all autistic cases by review of psychological and medical
records, including the Autism Diagnostic Interview-
Revised ([17]; ADI-R), and the Autism Diagnostic
Observation Schedule ([18]; ADOS) by a psychologist
with extensive diagnostic experience with autism (CCB;
Table 1). Seizure incidence of autistic cases was also
assessed through case records.
All cases were deceased, and were deidentified by the
brain banks where tissue was obtained. However, the
same human protections procedures were employed as
for live subjects. Research procedures employed in this
study were approved by the institutional review board of
the University of California, San Diego (protocol num-
ber 091205).
Brain sample collection
Due to documented variability of gene expression in
neighboring brain areas [19,20], it is of extreme impor-
tance that the blocks of tissue chosen for gene expres-
sion profiling are from comparable regions between
cases. Anatomical landmarks were identified as consis-
tently as possible for dissection across cases with the
goal of obtaining a set of highly controlled, comparable
tissue for brain gene expression profiling. When avail-
able, tissue from the superior frontal gyrus of the dorsal
lateral prefrontal cortex (DLPFC) was dissected in each
case. When this area was not available, we sampled
from the middle frontal gyrus. The formalin-fixed sam-
ples were obtained from larger areas of frontal cortex.
Cytoarchitecture and anatomical landmarks were also
used to determine the area of DLPFC similar to that of
the frozen tissue for dissection.
RNA Extraction from Tissues
E x t r a c t i o no ft o t a lR N Af r o m5 - 1 0m go ff r o z e nt i s s u e
from both grey and white matter, with as many layers of
cortex as possible, was performed using MELT
® kit
from Ambion according to manufacturer’si n s t r u c t i o n s
(http://www.ambion.com). Extraction of total RNA from
5-10 mg of formalin-fixed tissue sections was performed
using the Roche
® High Pure FFPE RNA Micro Kit.
Select RNA samples were analyzed with BioAnalyzer
®
(Agilent) according to the manufacturer’sp r o t o c o lf o r
quality control and quantification, and available RNA
Integrity Numbers (RIN) are reported in Table 1. Whole
RNA from remaining samples was quantified using a
NanoDrop
® spectrophotometer.
Figure 4 Sources of dataset variance. (A) Cluster dendrogram of
average linkage showing similarities between assays and tissue
types. Samples tended to cluster by assay type (IVT/DASL) and
preservation style (Frozen/Fixed). (B) To quantify the effects of these
predictors on the variance in the dataset, MDMR analysis was
conducted. Single and multiple regression MDMR analysis are
shown. Assay (IVT/DASL), source (Frozen/Fixed), batch, diagnosis,
age, and gender of case from which tissue samples were taken
were assessed. In the single regression model, each predictor is
assessed separately; in the multiple regression model, each predictor
is tested in relation with the other predictors in the model, yielding
a cumulative percent variance explained (PVE).
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Page 8 of 12DASL Labeling, Hybridization, and Scanning
Total RNA from reference samples, frozen, and forma-
lin-fixed cases underwent cDNA synthesis, and cDNA-
mediated annealing, selection, and ligation (DASL)-
based labeling, hybridization to Illumina HumanRef8 v3
and Human 12K microarrays (DASL assay on reference
RNA samples only), and scanning on two separate occa-
sions as described previously [7]. Both biological and
technical replicates were included for quality control.
Using biotinylated random primers and oligo-dT, 200
ng RNA was converted to cDNA. The biotinylated
cDNA was then immobilized to a streptavidin-coated
solid support, and annealed with a pool of gene-specific
oligonucleotides.
Following extension and ligation, the ligated oligonu-
cleotides were PCR amplified with a biotinylated and a
fluorophore-labeled universal primer, and captured
using streptavidin paramagnetic beads. Finally, the sin-
gle-stranded PCR products were eluted and hybridized
to the BeadChips at 58°C for 16 hours. A BeadArray
Reader was used to scan array images and extract fluor-
escence intensities, and all data were uploaded into
BeadStudio software without normalization or back-
ground subtraction for quality control and processing.
All raw data is available on the NCBI Gene Expression
Omnibus under accession number GSE28475 (http://
www.ncbi.nlm.nih.gov/geo/).
IVT Labeling, Hybridization, and Scanning
Gene expression profiling was performed on RNA from
reference samples, frozen, and fixed cases using the Illu-
mina Human Ref-8 v3 Expression BeadChip platform
(Illumina Inc., San Diego, CA, USA) according to manu-
facturer’s protocols. Following RNA extraction, an IVT
reaction for biotinylated cRNA was performed overnight
(~16 h). 750 ng cRNA were hybridized on the beadchip
at 58°C overnight and detected with Cyanine3-streptavi-
din. Arrays were again scanned with the Illumina Bea-
dArray Reader and read into Illumina GenomeStudio
software without normalization or background
subtraction.
Microarray data analysis
All data analyzed were raw and unprocessed. Probe
detection and signal information was directly output
from GenomeStudio. Probe concordance and self-repro-
ducibility were calculated based on technical replicates
in each category (frozen tissue-RNA assayed by IVT,
frozen tissue-RNA assayed by DASL, fixed tissue-RNA
assayed by IVT, fixed tissue-RNA assayed by DASL).
Table 2 Primer sequences for RTPCR validation.
Gene Name Forward Primer Sequence Reverse Primer Sequence
AIF1 CTCCAGCTTGGTCTGTCTCC TCATCCAGCCTCTCTTCCTG
CACNB1 ACGTCCTCGGATACCACATC CGGTCCTCCTCCAGAGATAC
CASP10 CTTTGGACCTTGGAGCACAC GAACTGGAATACCAATGTTGACC
CTTN GAAACAGGACCAAAAGCTTCC CATCTGGACACCAAACTTGC
EDEM3 GAATTTGAAGATGCAGTGAGAAAA AACTGCTTTGCCATTTGGAG
HAP1 GATGGAGGAGAACAGCAAGC GAATCTGAGTAGAGCTGGAGGAG
IL12RB1 CTGCCTGCAGAACCAGTGAG CAGCTGTGGGACCCTCATAC
LAMA2 TGTTTCTGTTCAGGGGTTTCA TGCTGATCTGCTGAGGTGAG
MTNR1B TCTTGGTGAGTCTGGCATTG TTGAAGACAGAGCCGATGAC
NEUROG2 CAAAGTCACAGCAACGCTGA GAGCAGCACTAACACGTCCTC
NFKB2 CCCTCCCATGGAGGACTG ACCAGACTGTGGGCATGAG
NRXN1 TCAGGAAATTCGCTTTGACC GTGTTGGTGATGCATTTTGG
OPN4 ACCCAGCTGGTGGGACAG CTGTGCCCAGGGTATAGTGG
OR2B6 TGAATTGGGTAAATGACAGCA CATGGGGGTATGAAGTTTGG
PROK1 CACCCCAAGTGACCATGAG CTCGAAGCCACAGGCTGAT
SRC AGATCCGCAAGCTGGACA CTGAGTCTGCGGCTTGGAC
TBX1 GTGTGAGCGTGCAGCTAGAG TCCATGAGCAGCATATAGTCG
TGFA CCTTGGTGGTGGTCTCCAT CGGTTCTTCCCTTCAGGAG
TLR1 AGGCCCTCTTCCTCGTTAGA AATGGCAAAATGGAAGATGC
RPL13A GGGAAGGGTTGGTGTTCAT GGGAAGGGTTGGTGTTCAT
ACTB GCCGTCTTCCCCTCCATC CGTCCCAGTTGGTGACGAT
TBP CGGCTGTTTAACTTCGCTTC CCAGCACACTCTTCTCAGCA
Forward and reverse primer sequences for 19 experimental and 3 reference genes used for RT-PCR to validate microarray results are shown.
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package Lumi [21-23] and Microsoft Excel. Cluster den-
drograms were generated by Lumi using Euclidean dis-
tance and average linkage clustering.
Multivariate Distance Matrix Regression
To assess the variance within the dataset attributable to
a set of variables before and after manipulating and pre-
processing the expression assay results (e.g. batch cor-
rection), multivariate distance matrix regression
(MDMR; [14]) with 1000 permutations was applied to
the Euclidean distance matrices constructed from the
expression values between each sample (http://poly-
morphism.scripps.edu/~cabney/cgi-bin/mmr.cgi). Vari-
ables of interest that were related to the expression
profiles reflected in the distance matrices included
batch, RNA source (reference RNA, frozen tissue, for-
m a l i n - f i x e dt i s s u e ) ,a s s a yt y p e( D A S Lo rI V T ) ,g e n d e r ,
diagnosis, and age of cases from which we sampled. We
leveraged both single independent variable and multiple
independent MDMR results. Case data analyzed by
MDMR as predictors (diagnosis, age, seizures) were
compiled by a clinical psychologist (C.C.B).
Independent qPCR Validation of Microarray Results
Genes and Cases
RNA from 1 male autistic and 1 male control case of 31
years was analyzed using SYBR green RT-PCR to vali-
date the intensity values detected by microarray. 19
genes were chosen with a wide range of fold change
values (positive and negative), and are listed in Table 2.
Using Primer3 software [24], primers of these genes
were designed across splice junctions to avoid artifacts
by genomic DNA contamination and to produce ampli-
cons of ~200 bp. RPL13A, B2M and ACTB, three genes
highly expressed in the brain at stable levels [25] were
chosen as reference genes for each experiment. Expres-
sion values for the remainder of the genes were normal-
ized to these reference gene controls.
cDNA Synthesis and qPCR
One microgram of total RNA was used for cDNA synth-
esis using random hexamers and AMV reverse tran-
scriptase. An equivalent of 50 ng of RNA was processed
by qPCR using Roche’s LightCycler rapid thermal cycler
system (Roche Diagnostics Ltd, Lewes, UK) according to
the manufacturer’s instructions, in a 96-well, 10-uL for-
mat using standard PCR conditions. 1 μL of cDNA tem-
plate, 250 nM of forward and reverse primer, and 5 μL
of qPCR Master Mix (Roche) were mixed for each
reaction.
Statistical analysis
According to Vandesompele et al., [25] we took the geo-
metric mean of all reference genes and the difference
between this mean and the average intensity of
experimental genes to find the delta Ct for each experi-
mental gene. Subsequently, log2 fold change was
assessed using -(T-C) where T = delta Ct of gene of the
autistic case, and C = delta Ct of gene of the control
case. Spearman’s rank correlation was then applied to
the results from the qPCR and microarray assays.
Additional material
Additional File 1: BioAnalyzer analysis showing reference RNA
fragmentation and RIN values for each sample. Artificially degraded
brain and pooled reference RNA was visualized using Agilent
BioAnalyzer. B0 and P0 samples show two ribosomal RNA bands, while
samples heated at 95°C showed smaller RNA fragments. The longer the
duration of heating, the smaller the fragments became. B0 = intact
reference brain RNA; B10 = 10 minute heating at 95°C; B30 = 30 minute
heating at 95°C; B60 = 60 minute heating at 95°C; P0 = intact reference
pooled RNA; P10 = 10 minute heating at 95°C; P30 = 30 minute heating
at 95°C; P60 = 60 minute heating at 95°C.
Additional File 2: Brain Reference RNA assay performance.
Scatterplots of reference RNA samples with increasing levels of artificial
degradation, histogram of data distribution, correlation, and number of
up- and downregulated genes differing between samples in IVT- (left)
and DASL- (right) based platforms are shown. Degraded brain reference
RNA profiled on IVT-based assays show lower correlations with intact
RNA than on DASL-based assays. Intensity values also cluster at
background levels for increasing RNA degradation for IVT-based samples
but not DASL-based samples. For example, correlations between intact
RNA and RNA degraded for 60 minutes (B60) differed greatly between
two assays (four corner boxes on the two plots). IVT_B60 had a
correlation of 0.5 (lower left corner box) with the intact sample (IVT_B0).
In contrast, DASL_B60 had a correlation of 0.82 with the intact sample
(DASL_B0). In addition, the histogram of IVT_B60 shows most intensity
values at background levels, but that of DASL_B60 showed a similar
distribution to that of DASL_B0. In addition, the scatterplot comparing
IVT_B0 and IVT_B60 (top right corner box) shows skewing from the y = x
line, reflecting the clustering of IVT_B60 intensities at background values.
The scatterplot comparing DASL_B0 and DASL_B60, however, shows
better adherence to the diagonal despite some dispersion. B0 = intact
reference brain RNA; B10 = 10 minute heating at 95°C; B30 = 30 minute
heating at 95°C; B60 = 60 minute heating at 95°C.
Additional File 3: Clustering of samples with similar levels of RNA
degradation evident in results from both IVT and DASL assays.
Average hierarchical clustering was applied to the Euclidean distance
between intact and artificially degraded brain and pooled reference RNA
samples. Thus the more degraded the sample is regardless of assay, the
less similar it is to the intact sample. Labels indicate assay type and time
of degradation. B0 = intact reference brain RNA; B10 = 10 minute
heating at 95°C; B30 = 30 minute heating at 95°C; B60 = 60 minute
heating at 95°C; P0 = intact reference pooled RNA; P10 = 10 minute
heating at 95°C; P30 = 30 minute heating at 95°C; P60 = 60 minute
heating at 95°C; B75P25 = 75% brain reference RNA and 25% pooled
reference RNA combination; B25P75 = 25% brain reference RNA and 75%
pooled reference RNA combination; rep = technical replicates.
Additional File 4: Intensity distributions vary with RNA degradation
in IVT- but not DASL-based assays. Boxplot showing the amplitude of
genome-wide intensity distributions detected for intact and artificially
degraded reference brain and pooled RNA samples processed by IVT-
and DASL-based platforms. In the IVT-processed samples, increasing RNA
degradation correlated with a smaller range of intensity values clustered
at low intensities. In the DASL-processed samples, this confound was not
observed. B0 = intact reference brain RNA; B10 = 10 minute heating at
95°C; B30 = 30 minute heating at 95°C; B60 = 60 minute heating at 95°C;
P0 = intact reference pooled RNA; P10 = 10 minute heating at 95°C; P30
= 30 minute heating at 95°C; P60 = 60 minute heating at 95°C; B75P25 =
75% brain reference RNA and 25% pooled reference RNA combination;
Chow et al. BMC Genomics 2011, 12:449
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combination; rep = technical replicate.
Additional File 5: Assay performance on formalin-fixed tissue.
Correlations between fixed tissue technical replicates and between
samples on IVT- (left) and DASL- (right) based platforms are shown.
Scatterplots of genome-wide profiling results from 2 formalin-fixed
samples (BTB3859 and UMB1670) processed by the two assays, histogram
of data distribution, correlation, and number of up and downregulated
genes show low reliability in profiling RNA from these samples in both
assays. Most intensity values tended to cluster at background levels,
particularly for the IVT-processed samples. For example, technical
replicates of BTB3859 (four top left boxes on two plots) show 0.83
correlation on the IVT-based assay, and 0.77 correlation on the DASL
assay. However, the histogram and scatterplots show that this correlation
on the IVT-based assay (left plot) is due to detection of most probes at
low background levels. In contrast, the histogram of the DASL-based
assay results for this case (right plot) shows a subset of probes that
showed some reliability, with intensity values above baseline. Rep =
technical replicate.
Additional File 6: RNA degradation in degraded frozen-tissue based
RNA affects IVT greater than DASL processing. Boxplots show
genome-wide intensity distribution of frozen brain-extracted RNA
samples from four cases and replicates processed by IVT- and DASL-
based assays. The IVT-processed samples clearly show distributions
clustered at background intensities especially for samples with low RIN
(2.2 for UMB4670 and 2.4 for UMB4721). The distribution of DASL-
processed samples for UMB4670 and UMB4721 did not appear
significantly different from samples with higher RIN (6.3 for UMB4849
and 4.9 for UMB1649). Rep = replicate.
Additional File 7: Low correlations between IVT- and DASL-based
assays on the same three frozen tissue-extracted RNA samples.
Scatterplots of 3 samples processed by the two assays, histogram of data
distribution, correlation, and number of up and downregulated genes
show low concordance between the same tissue sample processed by
two platforms, and differences in intensity distribution between
platforms. For example, the correlation between case UMB1349
processed by IVT- and DASL-based assays (IVT_UMB1349 and
DASL_UMB1349; four top left boxes) was 0.76. Histograms for this case
show a similar distribution for both assays, but the scatterplot shows
many probes diverging from the y = x line.
Additional File 8: Low correlation between processed samples of
UMB1796. Frozen and fixed samples taken from case UMB1796 were
processed by both IVT- and DASL-based methods. Genome-wide results
are plotted to compare correlations and distributions. Scatterplots of
UMB1796 replicates, histogram of data distribution, correlation, and
number of up- and downregulated genes differing between samples
show low correlations between brain tissue profiled using IVT- and
DASL-based approaches from the same case in all except DASL technical
replicates. Labels indicate assay type (DASL/IVT), preservation method
(Frozen/Fixed), sample code, and replicate number (if applicable).
Additional File 9: Log2 Fold Change Correlations of selected genes
detected by microarray and RTPCR. Log2 Fold change detected by
RTPCR is depicted on the x axis, and microarray on the y-axis of 19 up-
and down-regulated genes in the dataset. Spearman’s rank correlation
detected an R = 0.78 (p = 0.000075, DF = 17) correlation between
microarray and qPCR detection of fold change.
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